hondaboost
11月前
TNFA, will do 1 for 100 Reverse Splits.
A proposal to approve an amendment to our Certificate of Incorporation, as amended (the “Charter”), to effect, at the discretion of the board of directors (the “Board”) of the Company but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of our common stock, par value $0.001 per share, at a ratio in the range of 1-for-2 to 1-for-100, with such ratio to be determined by the Board in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”);
https://www.otcmarkets.com/filing/html?id=18482894&guid=Izo-kWz4RHpCJth
knrorrel
11月前
If found this info about TNFA:
Big movements in Tnf Pharmaceuticals, Inc. stock price on Tuesday moving 11.19% between high and low
July 22,
The Tnf Pharmaceuticals, Inc. stock price fell by -17.31% on the last day (Tuesday, 22nd Jul 2025) from $0.129 to $0.107. During the last trading day the stock fluctuated 11.19% from a day low at $0.103 to a day high of $0.114. The price has fallen in 6 of the last 10 days and is down by -10.83% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -344 million shares and in total, 41 million shares were bought and sold for approximately $4.38 million.
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -46.70% during the next 3 months and, with a 90% probability hold a price between $0.0447 and $0.0680 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
TNFA Signals & Forecast
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Tnf Pharmaceuticals, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $0.134. On a fall, the stock will find some support from the short-term average at $0.105. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Monday, July 21, 2025, and so far it has fallen -17.31%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Support, Risk & Stop-loss for Tnf Pharmaceuticals, Inc. stock
Tnf Pharmaceuticals, Inc. finds support from accumulated volume at $0.106 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.0115 between high and low, or 11.19%. For the last week, the stock has had daily average volatility of 21.47%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (TNFA) For The Upcoming Trading Day Of Wednesday 23rd
For the upcoming trading day on Wednesday, 23rd we expect Tnf Pharmaceuticals, Inc. to open at $0.108, and during the day (based on 14 day Average True Range), to move between $0.0965 and $0.118, which gives a possible trading interval of +/-$0.0211 (+/-21.88%) up or down from last closing price. If Tnf Pharmaceuticals, Inc. takes out the full calculated possible swing range there will be an estimated 21.88% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $0.106 (0.75%) than the resistance at $0.109 (1.87%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Insiders are Very Positive As Most New Trades Are Buy In Tnf Pharmaceuticals, Inc.
In the last 3 trades there were 225 thousand shares bought . The last trade was made 97 days ago by Rauch Gary M who bough 75 thousand shares. For the period there is more stocks sold than bought, but the most of the latest transactions are buy. This can indicate renewed interest by the insider, but also stock options expiring
Is Tnf Pharmaceuticals, Inc. stock A Buy?
Tnf Pharmaceuticals, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold to a Strong Sell candidate.
https://stockinvest.us/stock/TNFA
imho
INV4
11月前
So OS on otcmarkets.com is not correct? Based on below.
=====================
TNF Pharmaceuticals Approves Stock Amendment at Annual Meeting
June 06, 2025
• TNF Pharmaceuticals increased authorized common stock shares to 1.25 billion.
• Shareholders approved board authority to raise Series F stock value to $1,125.
On June 3, 2025, TNF Pharmaceuticals reconvened its 2025 annual stockholder meeting, initially adjourned from May 20, 2025. During the meeting, shareholders approved an amendment to increase the number of authorized common stock shares from 250 million to 1.25 billion. Additionally, a proposal was approved to allow the board to increase the stated value of Series F and F-1 Convertible Preferred Stock up to $1,125 per share. The meeting also saw the re-election of six directors and the ratification of Stephano Slack LLC as the independent auditor for 2025. These decisions are expected to enhance the company’s capital structure and governance, potentially impacting its market positioning and shareholder value.
More about TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates within the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is involved in the production of various types of stock, including common and preferred stocks, and is engaged in activities related to corporate governance and shareholder meetings.
https://www.tipranks.com/news/company-announcements/tnf-pharmaceuticals-approves-stock-amendment-at-annual-meeting
=====================
(Just trying to figure out what's going on here)
Compliance Period
TNF Pharmaceuticals has been granted a 180-day compliance period, ending on September 15, 2025, to regain compliance with the minimum bid price requirement.
Implications of a Reverse Split
Stock Price Recovery: If TNF Pharmaceuticals opts for a reverse split, it could help raise the stock price above the $1.00 threshold needed to avoid delisting.
Market Reaction
Reverse splits can carry a stigma, as they often indicate financial distress. However, they can also be a strategic move to stabilize the stock and attract institutional investors.
Conclusion
The situation for TNF Pharmaceuticals is critical as it navigates compliance issues and considers a reverse split to maintain its Nasdaq listing. The outcome of this period will be crucial for the company's future.
$TNFA